Optimising management of neutropenia and anaemia in cancer chemotherapy-advances in cytokine therapy.

[1]  K. Aoki,et al.  S7.7 The role of carbohydrate on the biological activity of erythropoietin , 1993, Glycoconjugate Journal.

[2]  M. Piccart,et al.  A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. , 2003, Oncology reports.

[3]  M. Piccart,et al.  A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  B. Emmerich,et al.  Randomized, dose‐finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies , 2002, British journal of haematology.

[5]  J. Glaspy,et al.  Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. , 2002, Oncology.

[6]  M. Fiegl,et al.  Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. , 2002, Journal of the National Cancer Institute.

[7]  G. Demetri,et al.  Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy , 2002, Cancer.

[8]  J. Glaspy,et al.  Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy , 2002, British Journal of Cancer.

[9]  F. Holmes,et al.  Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  E. Chrischilles,et al.  Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. , 2002, Cancer control : journal of the Moffitt Cancer Center.

[11]  L. R. Hill,et al.  Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  V. Morrison,et al.  The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. , 2001, Clinical lymphoma.

[13]  A. Riva,et al.  Taxane/anthracycline combinations: setting a new standard in breast cancer? , 2001, The oncologist.

[14]  I. Macdougall.  An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  R. Pirker,et al.  A phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum-treatment for lung cancer , 2001 .

[16]  A. Saven,et al.  Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer , 2001, British Journal of Cancer.

[17]  J. Egrie,et al.  Development and characterization of novel erythropoiesis stimulating protein (NESP) , 2001, British Journal of Cancer.

[18]  J. Armitage,et al.  2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Y. Ohashi,et al.  Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  J. Crawford,et al.  A phase II multicycle trial of pegfilgrastim compared to Filgrastim after myelosuppressive chemotherapy , 2000 .

[21]  J. Crawford,et al.  Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. Ulich,et al.  A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. , 1999, Experimental hematology.

[23]  I. Macdougall,et al.  Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.

[24]  V. Diéras,et al.  Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  G. Sroka-Perez,et al.  THE IMPACT OF BLOOD HEMOGLOBIN CONTENT ON THE OUTCOME OF RADIOTHERAPY : THE FREIBURG EXPERIENCE , 1998 .

[26]  Nowrousian Mr.  Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. , 1998, Medical oncology.

[27]  H. Ludwig,et al.  Anemia in cancer patients. , 1998, Seminars in oncology.

[28]  J. Koeller.  Clinical Guidelines for the Treatment of Cancer‐Related Anemia , 1998, Pharmacotherapy.

[29]  C. Taylor,et al.  Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Gabrilove,et al.  Filgrastim (r-metHuG-CSF): the first 10 years. , 1996, Blood.

[31]  Abels,et al.  Recombinant Human Erythropoietin (rHuEPO) for the Treatment of the Anemia of Cancer. , 1991, The oncologist.

[32]  A. Holleb,et al.  American Cancer Society textbook of clinical oncology , 1991 .

[33]  G. Friedell.  ANÆMIA IN CANCER , 1965 .